GSK licenses Chinese firm’s cancer drug in US$750 million deal

drug approval expired 72% Health

GSK agreed to acquire global rights to a cancer drug from Chinese biotechnology firm Chimagen Biosciences in a deal valued up to US$750 million. The drug is a T-cell engager targeting multiple myeloma, highlighting China's growing role in biotech innovation.

🇨🇳 Location: Chengdu — Sources: 2 — First seen: — Last seen:
GSK Chimagen Biosciences cancer drug multiple myeloma biotechnology

Linked Entities

Shengzhi Sun

person involved

Capital Medical University

organization involved

GSK

organization involved 🇺🇸

Chimagen Biosciences

organization involved

Contributing Articles